Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19(2):91–113.
Article CAS PubMed Google Scholar
Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67.
Article CAS PubMed PubMed Central Google Scholar
Lehmann BD, Jovanović B, Chen XI, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE. 2016. https://doi.org/10.1371/journal.pone.0157368.
Article PubMed PubMed Central Google Scholar
Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist. 2013;18(2):123–33.
Article CAS PubMed PubMed Central Google Scholar
Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21(7):1688–98.
Article CAS PubMed Google Scholar
Jiang YZ, Ma D, Suo C, et al. Genomic and Transcriptomic Landscape of Triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35(3):428–440e5.
Article CAS PubMed Google Scholar
Gucalp A, Traina TA. Triple-negative breast cancer: role of the androgen receptor [published correction appears in Cancer J. 2010 Nov-Dec;16(6):643]. Cancer J. 2010;16(1):62–65.
Gerratana L, Basile D, Buono G, et al. Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype. Cancer Treat Rev. 2018;68:102–10.
Article CAS PubMed Google Scholar
Gucalp A, Tolaney S, Isakoff SJ, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast Cancer. Clin Cancer Res. 2013;19(19):5505–12.
Article CAS PubMed PubMed Central Google Scholar
Bonnefoi H, Grellety T, Tredan O, et al. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12 – 1). Ann Oncol. 2016;27(5):812–8.
Article CAS PubMed Google Scholar
Traina TA, Miller K, Yardley DA, et al. Enzalutamide for the treatment of androgen receptor-expressing Triple-negative breast Cancer. J Clin Oncol. 2018;36(9):884–90.
Article CAS PubMed PubMed Central Google Scholar
Astvatsaturyan K, Yue Y, Walts AE, Bose S. Androgen receptor positive triple negative breast cancer: clinicopathologic, prognostic, and predictive features. PLoS ONE. 2018. https://doi.org/10.1371/journal.pone.0197827.
Article PubMed PubMed Central Google Scholar
Pistelli M, Caramanti M, Biscotti T, et al. Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. Cancers (Basel). 2014;6(3):1351–62.
Qu Q, Mao Y, Fei XC, Shen KW. The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis. PLoS ONE. 2013. https://doi.org/10.1371/journal.pone.0082650.
Article PubMed PubMed Central Google Scholar
Wang C, Pan B, Zhu H, et al. Prognostic value of androgen receptor in triple negative breast cancer: a meta-analysis. Oncotarget. 2016;7(29):46482–91.
Article PubMed PubMed Central Google Scholar
Kim Y, Jae E, Yoon M. Influence of androgen receptor expression on the survival outcomes in breast Cancer: a Meta-analysis. J Breast Cancer. 2015;18(2):134–42.
Article PubMed PubMed Central Google Scholar
Asano Y, Kashiwagi S, Goto W, et al. Expression and clinical significance of androgen receptor in Triple-negative breast Cancer. Cancers (Basel). 2017. https://doi.org/10.3390/cancers9010004.
Bi J, Wu Z, Zhang X, et al. TMEM25 inhibits monomeric EGFR-mediated STAT3 activation in basal state to suppress triple-negative breast cancer progression. Nat Commun. 2023. https://doi.org/10.1038/s41467-023-38115-2.
Article PubMed PubMed Central Google Scholar
Lehmann BD, Bauer JA, Schafer JM, et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res. 2014. https://doi.org/10.1186/s13058-014-0406-x.
Article PubMed PubMed Central Google Scholar
Coussy F, Lavigne M, de Koning L, et al. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. Theranostics. 2020;10(4):1531–43.
Article CAS PubMed PubMed Central Google Scholar
Juric D, Janku F, Rodón J, et al. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-type estrogen receptor-positive advanced breast Cancer: a phase 1b clinical trial. JAMA Oncol. 2019. https://doi.org/10.1001/jamaoncol.2018.4475.
Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36(20):2105–22.
Article CAS PubMed Google Scholar
Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008;14(16):5158–65.
Article CAS PubMed Google Scholar
Xin L, Wu Q, Zhan C, et al. Multicenter study of the clinicopathological features and recurrence risk prediction model of early-stage breast cancer with low-positive human epidermal growth factor receptor 2 expression in China (Chinese society of breast surgery 021). Chin Med J (Engl). 2022;135(6):697–706.
Article CAS PubMed Google Scholar
Bose R, Kavuri SM, Searleman AC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2013;3(2):224–37.
Article CAS PubMed Google Scholar
Zuo WJ, Jiang YZ, Wang YJ, et al. Dual characteristics of Novel HER2 kinase domain mutations in response to HER2-Targeted therapies in human breast Cancer. Clin Cancer Res. 2016;22(19):4859–69.
Article CAS PubMed Google Scholar
O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016;13(7):417–30.
Cai Z, Wang J, Li Y, et al. Overexpressed cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors. Sci China Life Sci. 2023;66(1):94–109.
Article CAS PubMed Google Scholar
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.
Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33.
Article CAS PubMed PubMed Central Google Scholar
Dvinge H, Git A, Gräf S, et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature. 2013;497(7449):378–82.
Article CAS PubMed Google Scholar
Mulrane L, McGee SF, Gallagher WM, O’Connor DP. miRNA dysregulation in breast cancer. Cancer Res. 2013;73(22):6554–62.
Article CAS PubMed Google Scholar
Shi Y, Yang F, Sun Z, Zhang W, Gu J, Guan X. Differential microRNA expression is associated with androgen receptor expression in breast cancer. Mol Med Rep. 2017;15(1):29–36.
Article CAS PubMed Google Scholar
Angelova M, Charoentong P, Hackl H, et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 2015. https://doi.org/10.1186/s13059-015-0620-6.
Article PubMed PubMed Central Google Scholar
O’Meara T, Safonov A, Casadevall D, et al. Immune microenvironment of triple-negative breast cancer in African-American and caucasian women. Breast Cancer Res Treat. 2019;175(1):247–59.
Article PubMed PubMed Central Google Scholar
Goff SL, Danforth DN. The role of Immune cells in breast tissue and immunotherapy for the treatment of breast Cancer. Clin Breast Cancer. 2021. https://doi.org/10.1016/j.clbc.2020.06.011.
留言 (0)